Table of contents
Editorial: The time is now
p613 | doi:10.1038/nrd1817
News and Analysis
BiDil raises questions about race as a marker | PDF (150 KB)
p615 | doi:10.1038/nrd1812
Neuroimaging heats up | PDF (88 KB)
p616 | doi:10.1038/nrd1813
Indian generics companies go on spending spree | PDF (105 KB)
p616 | doi:10.1038/nrd1815
News in Brief
Stronger warnings needed for asthma treatments | Relationship problems for flu drug companies | Brazil and Abbott clash over AIDS drug | FDA restricts Iressa use | Impotence drugs receive blindness warning | Study casts doubts on studies | FDA to decide on morning-after contraceptive | Parkinson's drugs can cause compulsive gambling | PDF (234 KB)
p618 | doi:10.1038/nrd1816
Patent watch
No winners in Rasmusson versus SKB case | PDF (594 KB)
p620 | doi:10.1038/nrd1814
Purdue pharma loses OxyContin patent appeal | PDF (594 KB)
p620 | doi:10.1038/nrd1820
Patent primer
The Orange Book | PDF (80 KB)
p621 | doi:10.1038/nrd1804
Career Path
David T. Wong | PDF (101 KB)
p622 | doi:10.1038/nrd1811
From the analyst's couch
Therapeutic cancer vaccines | PDF (202 KB)
p623 | doi:10.1038/nrd1802
Fresh from the Pipeline
Rasagiline | PDF (147 KB)
p625 | doi:10.1038/nrd1803
Research Highlights
G-Protein-coupled receptors: It takes two... | PDF (220 KB)
p627 | doi:10.1038/nrd1805
Inflammation: The nerve of macrophages | PDF (195 KB)
p628 | doi:10.1038/nrd1806
RNA interference: Silence of the genes | PDF (391 KB)
p628 | doi:10.1038/nrd1809
Antiviral drugs: Breakthrough for HCV research | PDF (275 KB)
p629 | doi:10.1038/nrd1808
Screening: Won't get fooled again | PDF (173 KB)
p630 | doi:10.1038/nrd1807
In brief
Kinases | Infectious diseases | Anticancer drugs | Parkinson's disease | PDF (173 KB)
p630 | doi:10.1038/nrd1810
Perspectives
Article series: Model organisms
Opinion
The ultimate model organism: progress in experimental medicine
Bruce H. Littman & Stephen A. Williams
p631 | doi:10.1038/nrd1800
Opinion
Pharmacogenetics-based therapeutic recommendations — ready for clinical practice?
Julia Kirchheiner, Uwe Fuhr & Jürgen Brockmöller
p639 | doi:10.1038/nrd1801
Reviews
Computer-based de novo design of drug-like molecules
Gisbert Schneider & Uli Fechner
p649 | doi:10.1038/nrd1799
Leukotriene modifiers as potential therapeutics for cardiovascular disease
Colin D. Funk
p664 | doi:10.1038/nrd1796
The vagus nerve and the nicotinic anti-inflammatory pathway
Luis Ulloa
p673 | doi:10.1038/nrd1797
Asymmetry on large scale: the roadmap to stereoselective processes
Hans-Jürgen Federsel
p685 | doi:10.1038/nrd1798
Correction: HDL as a target in the treatment of atherosclerotic cardiovascular disease
Patrick Linsel-Nitschke & Alan R. Tall
| doi:10.1038/nrd1819
